Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

  • Technology appraisal guidance
  • TA258
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group (LRiG):

  • Bagust A, Beale S, Blundell M, et al. Erlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer, December 2011

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist, patient or carer groups, and other consultees, had the opportunity to give their expert views. Manufacturers or sponsors, professional or specialist and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Roche

Professional or specialist, and patient or carer groups:

  • Roy Castle Lung Cancer Foundation

  • British Thoracic Society

  • Cancer Research UK

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

Other consultees:

  • Department of Health

  • Welsh Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisal Services

  • Department of Health, Social Services and Public Safety – Northern Ireland

  • Healthcare Improvement Scotland

  • AstraZeneca UK

  • Lilly UK

  • Pfizer

  • Liverpool Reviews and Implementation Group

  • National Institute for Health Research Health Technology Assessment Programme

  • British Thoracic Oncology Group

  • National Collaborating Centre for Cancer

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on erlotinib by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Michael Lind, Foundation Professor of Oncology, nominated by Lilly – clinical specialist

  • Dr Sanjay Popat, Consultant Medical Oncologist, nominated by Royal College of Physicians – clinical specialist

Representatives from the following manufacturer or sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Roche Products Ltd

ISBN: 978-1-4731-6714-8